In high HIV prevalence area, TB is the most common cause of mortality. TB patients are the most important high risk population to be infected by HIV. Therefore, knowing the HIV status in the TB patients is vital to reduce TB mortality by prevention and control of HIV/TB co-infection. As with other studies elsewhere, majority of the TB patients did not take part in HIV testing because of fear of being stigmatized due to anticipated consequence of testing HIV positive. This study addressed the status of HIV in participants with pulmonary tuberculosis.
The overall HIV prevalence rate in the pulmonary TB patients was 7.6% which was consistent with WHO report (
8). Overall WHO estimation for HIV prevalence in new diagnosed TB patients worldwide is 8% (
8). Regardless of IDU cases, HIV prevalence rate in the current study was similar to other studies reported by Zhou
et al. (China, 2008), Tang
et al. (China, 2009) and Talebimehr (Iran, 2008), but lower than the rate reported by Ipuge
et al. (Tanzania, 2009) and Daftary
et al. (South Africa, 2007) (
17-
21). Reported HIV prevalence rate (
17-
21) ranges from 2.27% (Iran) and 2.3% (China) to 44% (Tanzania) and 60% (South Africa). There are many reasons for these differences; HIV prevalence among pulmonary TB depends on various factors such as: HIV status in the region under study (e.g. high prevalence or low prevalence area), design of study (e.g. population based or hospital based study) and behaviors of the subjects under study(e.g. IDUs or unsafe sex contacts) (
17-
19,
21-
23).
According to WHO classification; South Africa and Tanzania are defined as HIV high prevalence area (more than 5% of general population are infected by HIV), while, China and Iran are categorized as HIV low prevalence area (lower than 1% general population are HIV infected). The current study was a hospital based study while other studies were population based. Although, the overall prevalence of HIV in the pulmonary TB was 7.6%, this status was not hemogenous. HIV prevalence in IDU pulmonary TB patients was significantly higher than that in non-IDU pulmonary TB patients (66.6% vs. 2.1%). In spite of the recommendation of HIV testing to all TB patients in high HIV prevalence setting (
6), because of low HIV prevalence among the non-IDU tuberculosis patients (2.1%), compared with HIV high prevalence regions (more than 5%), routine HIV testing of patients with tuberculosis (
21) in the region under study is not cost benefit.
The current study does however offer HIV testing into TB patients in a specific context such as IDU subjects with high HIV prevalence due to their sharing needles and syringes (
12,
19). The present study did not address the roles of gender, age, residency and occupation; whereas it was observed that female and older TB patients were at lower risk of HIV infection. The reason for such condition may be due to the life style and behavior of the patients under study (
11,
12). Indeed, factors such as residency, age, gender and occupation are not real risk factors for HIV acquisition.
The present study found that in the region under study, HIV prevalence in newly detected pulmonary TB patients (except in IDU patients) was low, compared with HIV high prevalence regions. Therefore, undergoing routine HIV testing in national TB program may not be required.